Features of intellectual property protection mechanisms on the example of orphan drugs circulation

Objective: to study features of intellectual property protection mechanisms on the example of drugs for the treatment of rare (orphan) diseases.
Material and methods. Analysis of pharmaceutical market data was performed with the DSM Group analytical database. The approach proposed by the Russian Federal Industrial Property Service was used for creating patent landscape. The method supposes conducting a patent search and analysis of the documents found for date of filing, office (country) of filing, applicant, as well as analysis of the patent activity (dynamics) for the subject, in this case, for orphan drugs having a defined structure.
Results. We proposed the complex conclusions to increase national drug safety. Intellectual property limitations for importing countries such as data exclusivity, do not allow to reproduce clinical trials, which leads to non-disclosure of medical data to all parties – medical society and patients, all other market participants, including local pharmaceutical producers. Current intellectual property restrictions conceal crucial data from medical and patient society and other market players and affect accuracy of diagnosis and treatment. Along with outstanding cost of new therapies it causes enormous budget burden for the healthcare system and prevents the introduction of objective criteria in the appointment and use of medicines. Prior to the approval and submission of the registration certificate by the regulatory authority, it is necessary to establish reasonable marginal prices, to form a sufficient set and volume of clinical guidelines and to determine in advance the sources of financing and mechanisms of integration into the national system of drug provision.
Conclusion. The introduction of drugs for the treatment of rare diseases into circulation leads to a sharp increase in the burden on the budgets of the healthcare system at all levels. Current restrictions and obligations in the field of intellectual property rights protection, the degree of disclosure of medical data in the process of registration and admission to the market require significant changes to the traditional system of drug provision and the system of placing state orders, as well as the introduction of new regulatory mechanisms (for example, compulsory licensing or producing individual dosage forms in pharmacy organizations), contributing to the development of the local pharmaceutical industry and providing the national health system with the necessary volume of drugs with a sufficient level of quality and safety.

1. Herder M. What is the purpose of the Orphan Drug Act? PLoS Med. 2017; 14 (1): e1002191. https://doi.org/10.1371/journal.pmed.1002191.

2. Medicines act. Chapter 176, section 9. Medicines (orphan drugs) (exemption) order O 12. G.N. №. S 470/1991. Revised edition 2005 (31st March 2005). Available at: https://sso.agc.gov.sg/SL-Rev/MA1975-OR12/Published/20050331?DocDate=20050331 (accessed 15.02.2021).

3. Ministry of Health, Labour and Welfare. Overview of Orphan Drug/ Medical Device Designation System. Available at: https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html (accessed 15.02.2021).

4. Australian Government. Department of Health. Orphan drugs program. Discussion paper. Available at: https://www.tga.gov.au/sites/default/files/consultation-orphan-drugs-program.pdf (accessed 15.02.2021).

5. Regulation (EC) No. 141/2000 Of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (OJ L 18, 22.1.2000, p. 1). Available at: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf (accessed 15.02.2021).

6. Pallavi K., Vineela B., Ramadoss K., Srinivasa B.P. An upshot for the remedy of rare diseases: orphan drugs. The Indian Pharmacist. May, 2012.

7. Order of the Ministry of Health of the RF of 13.02.2013 No. 66 (as amended of December 29, 2020) “On approval of the strategy for drug provision of the population of the Russian Federation for the period up to 2025 and the plan for its implementation”. Available at: http://www.consultant.ru/document/cons_doc_LAW_142725/ (in Russ.) (accessed 10.09.2021).

8. Orphan drugs in the United States. Rare disease innovation and cost trends through 2019. Available at: https://www.iqvia.com/insights/theiqvia-institute/reports/orphan-drugs-in-the-united-states-rare-diseaseinnovation-and-cost-trends-through-2019 (accessed 15.02.2021).

9. Order of the Government of the RF No. 2798-r of 28.10.2020 “On creation of the federal state institution Federal Center for Planning and Organization of Drug Provision of Citizens”. Available at: http://www.consultant.ru/cons/cgi/online.cgi?req=doc&base=EXP&n=753687#zJbDdpSeUBfH47TK (in Russ.) (accessed 02.03.2021).

10. Decree of the President of the RF No. 16 of 05.01.2021 “On the creation of a fund to support children with severe life-threatening and chronic diseases, including rare (orphan) diseases, Circle of Goodness”. Available at: https://www.garant.ru/products/ipo/prime/doc/400068476/ (in Russ.) (accessed 15.02.2021).

11. Audit of retail and governmental pharmaceutical market in RF. Analytical database of marketing agency DSM Group. Available at: https://dsmviewer.ru/ (in Russ.) (accessed 15.02.2021).

12. Order of Rospatent of 23.01.2017 No. 8 “Methodic recommendations for preparing reports of patent reviews (patent landscape)”. Available at: http://www.consultant.ru/document/cons_doc_LAW_212062/ (in Russ.) (accessed 01.02.2021).

13. WIPO Patentscope. Available at: https://patentscope.wipo.int/search/ru/search.jsf (in Russ.) (accessed 01.02.2021).

14. Federal Institute of Industrial Property. Available at: https://new.fips.ru/iiss/ (in Russ.) (accessed 01.02.2021).

15. USPTO. United States PATENT AND Trademark Office. Available at: https://www.uspto.gov/ (accessed 01.02.2021).

16. Espacenet. Patent Search. Available at: https://worldwide.espacenet.com/ (accessed 01.02.2021).

17. Federal Treasury. Consolidated budgets of the subjects of the Russian Federation and budgets of territorial state extra-budgetary funds. Available at: https://roskazna.gov.ru/ispolnenie-byudzhetov/ (in Russ.) (accessed 15.02.2021).

18. State Duma Committee on Health Protection. Annual bulletin of the Expert Council on Rare (Orphan) Diseases. Мoscow; 2020: 332 pp. (in Russ.).

19. Federal Law No. 299-FZ of 03.08.2018 “On amendments to the Federal Law On the Basics of Public Health Protection in the Russian Federation”. Available at: http://www.consultant.ru/document/cons_doc_LAW_304049/ (in Russ.) (accessed 15.02.2021).

20. Federal Law No. 452-FZ of 27.12.2019 “On amendments to the Federal Law On the Basics of Public Health Protection in the Russian Federation”. Available at: http://www.consultant.ru/document/cons_doc_LAW_341765/ (in Russ.) (accessed 15.02.2021).

21. Order of the Government of the RF No. 2053-r of 31.12.2008 “On the list of medicines centrally purchased at the expense of the federal budget”. Available at: http://www.consultant.ru/document/cons_doc_LAW_83559/ (in Russ.) (accessed 15.02.2021).

22. Resolution of the Government of the RF No. 1416 of 26.11.2018 “On the procedure for organizing the provision of medicines to persons with hemophilia, cystic fibrosis, pituitary nanism, Gaucher's disease, malignant neoplasms of lymphoid, hematopoietic and related tissues…” Available at: http://www.consultant.ru/document/cons_doc_LAW_311869/ (in Russ.) (accessed 15.02.2021).

23. Resolution of the Government of the RF No. 403 of 26.04.2012 “On the procedure for maintaining the Federal Register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases that lead to a reduction in the life expectancy of citizens or their disability, and its regional segment”. Available at: http://www.consultant.ru/document/cons_doc_LAW_129078/ (in Russ.) (accessed 15.02.2021).

24. Resolution of the Government of the RF No. 829 of 05.06.2020 “ On amendments to certain acts of the Government of the Russian Federation on improving drug provision”. Available at: http://www.consultant.ru/document/cons_doc_LAW_354610/ (in Russ.) (accessed 15.02.2021).

25. Yurochkin D.S., Leshkevich A.A., Golant Z.M., Narkevich I.A. Comparison and analysis of the FDA approved orphane drugs register and the vital and essential drugs list of the Russian Federation. Remedium. 2020; 9: 4–16 (in Russ.).

26. State Register of Medicines. Registration certificate LSR-008892/09 of 05.11.2009. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5eae3847-1de9-409f-b1ce-0ea87af4484f&t= (in Russ.) (accessed 01.02.2021).

27. State Register of Medicines. Registration certificate LP-006771 of 11.02.2021. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1b59838f-2f56-43b0-a7ac-72ec75301ecb&t= (in Russ.) (accessed 01.02.2021).

28. State Register of Medicines. Registration certificate LP-001975 of 23.01.2013. Available at: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=7f530e7c-6c00-49ba-9a77-5a14edaf03ea&t= (in Russ.) (accessed 01.02.2021).

29. Iminosaccharide in crystalline form. Russian Patent RU2678085C2. Available at: https://patents.google.com/patent/RU2678085C2/ru (in Russ.) (accessed 01.02.2021).

30. Miglustat N-butyl-1,5-dideoxy-1,5-imino-D-glucite. Russian Patent RU2743694C1. Available at: https://patenton.ru/patent/RU2743694C1 (in Russ.) (accessed 01.02.2021).

31. The use of glucosidase inhibitors for the treatment of mucoviscidosis. Russian Patent RU2358725C2. Available at: https://patenton.ru/patent/RU2358725C2 (in Russ.) (accessed 01.02.2021).

32. Compositions and methods for the treatment of Gaucher's disease. Russian Patent RU2568831C2. Available at: https://www.fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2568831&T ypeFile=html (in Russ.) (accessed 01.02.2021).

33. IQVIA Institute for Human Data Science. Orphan drugs in the United States: growth trends in rare disease treatments. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports/orphan-drugs-inthe-united-states-growth-trends-in-rare-disease-treatments (accessed 15.02.2021).

34. Resolution of the Government of the RF No. 305 of 15.04.2014 “On approval of the state program of the Russian Federation Development of the Pharmaceutical and Medical Industry”. Available at: https://docs.cntd.ru/document/499091775 (in Russ.) (accessed 15.02.2021).

35. Resolution of the Government of the RF No. 514 of 31.03.2021 “On amendments to the state program of the Russian Federation Development of the Pharmaceutical and Medical Industry”. Available at: https://docs.cntd.ru/document/603209626 (in Russ.) (accessed 18.05.2021).

36. Resolution of the Government of the RF of 03.12.2020 No. 2001 “On amendments to certain acts of the Government of the Russian Federation”. Available at: http://www.consultant.ru/document/cons_doc_LAW_370118/ (in Russ.) (accessed 15.05.2021).

37. Resolution of the Government of the RF No. 1464 of 16.10.2019 “On approval of the Rules for granting subsidies from the federal budget to Russian organizations for financial support of part of the costs of implementing projects for the development of modern technologies, organization of production and sale of competitive medicines, and On the invalidation of certain acts of the Government of the Russian Federation”. Available at: http://www.consultant.ru/document/cons_doc_LAW_338042/ (in Russ.) (accessed 15.05.2021).

38. U.S. Food and Drug Adminisration. Accelerated approval. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapyaccelerated-approval-priority-review/accelerated-approval (accessed 15.02.2021).

39. European Medicines Agency. Conditional marketing authorisation. Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/conditional-marketing-authorisation (accessed 15.02.2021).

40. Federal Law No. 61-FZ of 12.04.2010 “On the circulation of medicines”. Available at: http://www.consultant.ru/document/cons_doc_LAW_99350/ (in Russ.) (accessed 15.02.2021).